


PATENT  
ATTORNEY DOCKET NO. 50026/054001

Certificate of Mailing	
Date of Deposit: <u>August 22, 2006</u>	Label Number: <u>EV 919882430 US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
<u>Elvis De La Cruz</u>	
Printed name of person mailing correspondence	Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Hamada et al.	Confirmation No.:	8449
Serial No.:	10/546,000	Art Unit:	Not Yet Assigned
Filed:	August 18, 2005	Examiner:	Not Yet Assigned
Customer No.:	21559		
Title:	METHODS FOR TREATING ISCHEMIC DISEASES		

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. A copy of a search report from a corresponding European application is also enclosed.

Jones et al. ("Gene Therapy for Gastric Ulcers with Single Local Injection of Naked DNA Encoding VEGF and Angiopoietin-1," *Gastroenterology* 121(5): 1040-1047, 2001) and Sim et al. ("Therapeutic Angiogenesis for Coronary Artery Disease," *Journal of Cardiac Surgery* 17(4): 350-354, 2002) are listed on the enclosed search report and


were cited in the present application in the Information Disclosure Statement ("IDS")  
filed July 7, 2006. These references are accordingly not cited in the present IDS.

Submission of this statement is not a representation that a search has been made,  
nor is the inclusion of information in this statement an admission that the information is  
material to patentability.

This statement is being filed before the receipt of a first Office action on the  
merits. If there are any charges or any credits, please apply them to Deposit Account No.  
03-2095.

Date: August 22, 2006

Respectfully submitted,

  
Reg No 57,727 for  
James D. DeCamp, Ph.D.  
Reg. No. 43,580

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50026/054001
	Serial No.	10/546,000
	Applicant	Hamada et al.
	Filing Date	August 18, 2005
	Group	Not yet assigned
	IDS Filed	August 22, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Jin et al., "Recombinant Sendai Virus Provides a Highly Efficient Gene Transfer into Human Cord Blood-Derived Hematopoietic Stem Cells," <i>Gene Ther.</i> 10(3): 272-277, 2003.					
	Kobune et al., "Telomerized Human Multipotent Mesenchymal Cells Can Differentiate into Hematopoietic and Cobblestone Area-Supporting Cells," <i>Exp. Hematol.</i> 31(8): 715-722, 2003.					
	Mah et al., "Virus-Based Gene Delivery Systems," <i>Clin. Pharmacokinet.</i> 41(12): 901-911, 2002.					
	Moyon et al., "Selective Expression of Angiopoietin 1 and 2 in Mesenchymal Cells Surrounding Veins and Arteries of the Avian Embryo," <i>Mech. Dev.</i> 106(1-2): 133-136, 2001.					
	Okano et al., "Recombinant Sendai Virus Vectors for Activated T Lymphocytes," <i>Gene Ther.</i> 10(16): 1381-1391, 2003.					
	Shiotani et al., "Skeletal Muscle Regeneration after Insulin-Like Growth Factor I Gene Transfer by Recombinant Sendai Virus Vector," <i>Gene Ther.</i> 8(14): 1043-1050, 2001.					
	Suri et al., "Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis," <i>Cell</i> 87(7): 1171-1180, 1996.					
	Takahashi et al., "Adenoviral-Delivered Angiopoietin-1 Reduces the Infarction and Attenuates the Progression of Cardiac Dysfunction in the Rat Model of Acute Myocardial Infarction," <i>Mol. Ther.</i> 8(4): 584-592, 2003.					
	Tsuda et al., "Efficient BMP2 Gene Transfer and Bone Formation of Mesenchymal Stem Cells by a Fiber-Mutant Adenoviral Vector," <i>Mol. Ther.</i> 7(3): 354-365, 2003.					
	European Search Report from European Patent Application No. 04706870.5, July 20, 2006.					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	